By Priyanjana Pramanik, MSc. A controlled crossover trial finds that short-term consumption of unprocessed beef is on par ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the ...

India: Researchers have discovered in a new study that using a diabetes-specific protein supplement as a partial breakfast replacement improves blood glucose control in people with type 2 diabetes ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical ...

Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...

Qnovia, Inc., a pharmaceutical and medtech company revolutionizing inhaled therapeutics, today announced positive results from its Phase 1 clinical trial evaluating the safety and efficacy of ...

As with randomization, if allocation to the study drug is not carried out in accordance with the protocol, the entire study ...

Michael Schmidt Guggenheim Securities, LLC, Research Division. All right. So daraxonrasib, obviously, there's been a lot of focus on the upcoming phase. The first randomized Phase ...

Starting the day with a sugary pastry might feel like a treat, but new research suggests it could sabotage your workday ...

Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 February 11, 2026 6:30 ...

TOKYO, Feb. 2, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million (1) ) in six R&D projects ...